Filing Details
Outlook Therapeutics, Inc. (NASDAQ:OTLK) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 18, 2026.
The Healthcare company reported Q0 revenue of .
10q filedNASDAQ:OTLK
Outlook Therapeutics, Inc. (OTLK) Files Quarterly Report for Q0
Outlook Therapeutics, Inc. (NASDAQ:OTLK) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 18, 2026.
At publication ·
What changed
Outlook Therapeutics, Inc. (NASDAQ:OTLK) · 10q filed
- Form
- 10-Q
At a glance
Key takeaways
- Outlook Therapeutics, Inc. (NASDAQ: OTLK) filed its quarterly 10-Q report on August 18, 2026, providing unaudited financial statements and management commentary on recent business performance.
- The company's stock trades at $0.70 per share with a market capitalization of $89.3 million as of the filing date.
- The quarterly report includes updated risk factors and information about changes in business conditions since the previous filing, though specific revenue figures were not disclosed in this summary.
Market Context
Outlook Therapeutics, Inc.'s stock currently trades at $0.70 with a market capitalization of $89.3M.
The 10-Q provides Outlook Therapeutics, Inc.'s quarterly financial update, including unaudited financial statements and management commentary on recent performance. While less detailed than the annual 10-K, the 10-Q often contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
All SEC filings for Outlook Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View OTLK Stock Page
Frequently Asked Questions
Where can I read OTLK's SEC filings?
Browse all filings on our OTLK SEC filings page.
What types of SEC filings does Outlook Therapeutics, Inc. file?
Public companies like Outlook Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.